In-vitro activity of plazomicin, meropenem-vaborbactam, and omadacycline against carbapenem-resistant Gram-negative isolates in Egypt

Gadallah, Mona; El-Sayed, Wasila Moursy; Hussien, Mohammed Zakaria; Elheniedy, Mohammed Ahmed; Maxwell, Sara Youssef

doi:10.1080/1120009x.2022.2095156

Cited by 2 publications

(1 citation statement)

References 53 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The antimicrobial could inhibit most gentamycin, tobramycin, and amikacin-resistant isolates [ 98 ]. Moreover, the drug retains in vitro activity against two-thirds of CR isolates, more than MER/VARB and OMA [ 99 ]. Of interest, plazomicin may remain active against MBL-producing Enterobacterales.…”

Section: Recently Approved Antimicrobial Agentsmentioning

confidence: 99%

Novel Antimicrobial Agents for Gram-Negative Pathogens

et al. 2023

View full text Add to dashboard Cite

Gram-negative bacterial resistance to antimicrobials has had an exponential increase at a global level during the last decades and represent an everyday challenge, especially for the hospital practice of our era. Concerted efforts from the researchers and the industry have recently provided several novel promising antimicrobials, resilient to various bacterial resistance mechanisms. There are new antimicrobials that became commercially available during the last five years, namely, cefiderocol, imipenem-cilastatin-relebactam, eravacycline, omadacycline, and plazomicin. Furthermore, other agents are in advanced development, having reached phase 3 clinical trials, namely, aztreonam-avibactam, cefepime-enmetazobactam, cefepime-taniborbactam, cefepime-zidebactam, sulopenem, tebipenem, and benapenem. In this present review, we critically discuss the characteristics of the above-mentioned antimicrobials, their pharmacokinetic/pharmacodynamic properties and the current clinical data.

show abstract

Section: Recently Approved Antimicrobial Agentsmentioning

confidence: 99%